Assistive technology (A.T.) is an umbrella term covering the systems and services related to the delivery of assistive products such as wheelchairs, eyeglasses, hearing aids, prosthetics, and personal communication devices. Today, over 1 billion people require A.T. to achieve their full potential, but 90% do not have access to the A.T. that they need. 1 This unmet need for A.T. is driven by a lack of awareness of this need, discrimination and stigma, a weak enabling environment, lack of political prioritisation, limited investment and market barriers on the demand and supply side. Narrowing in on the market shortcomings that limit the availability of assistive products, market shaping is proposed to address the root causes that limit availability, affordability and access of appropriate A.T. with the wider aim of ensuring improved social, health and economic outcomes for people who require A.T.. To accelerate access to A.T., the global community needs to leverage the capabilities and resources of the public, private, and non-profit sectors to harness innovation and break down market barriers.
Whether by reducing the cost of antiretroviral drugs for H.I.V. by 99% in 10 years, increasing the number of people receiving malaria treatment from 11 million in 2005 to 331 million in 2011, 2 or doubling the number of women receiving contraceptive implants in 4 years while saving donors and governments U.S.$240 million, 3 market shaping has addressed market barriers at scale. Market shaping interventions can play a role in enhancing market efficiencies, improving information transparency, and coordinating and incentivising the numerous stakeholders involved in both demand and supply-side activities. Examples of market shaping interventions include: pooled procurement, de-risking demand, bringing lower cost and high-quality manufacturers into global markets, developing demand forecasts and market intelligence reports, standardising specifications across markets, establishing differential pricing agreements, and improving service delivery and supply chains.
4FIGURE 1: ENGAGING BOTH DEMAND- AND SUPPLY-SIDE FOR MARKET SHAPING
| DEMAND SIDE ENGAGEMENT | SUPPLY SIDE ENGAGEMENT |
Hearing loss that prevents hearing at thresholds lower than 40 decibels (d.B.) in the better hearing ear in adults and lower than 30 d.B. in the better hearing ear in children is known as disabling hearing loss. 4 More than 5% of the global population—or 466 million people—have disabling hearing loss, with 34 million of these being children. 5 It is the fourth leading cause of disability globally. 6 Approximately 90% of people with hearing loss live in low- and middle-income countries (L.M.I.C.s) with prevalence rates almost four times that of high-income regions. 7
Multiple causes for hearing loss exist, but they can primarily be placed into two categories: congenital and acquired factors. Congenital causes include genetic causes and complications due to pregnancy or childbirth such as maternal infections (especially congenital syphilis), birth asphyxia, exposure to certain drugs during pregnancy, and low birth weight or jaundice. It is estimated that five out of every 1,000 babies are born with hearing loss or acquire it soon after birth in one or both ears. Acquired causes can occur at any age and include infectious diseases, such as mumps, measles or rubella, chronic ear infections, use of ototoxic medicines (i.e. medicines known to damage cells in the ear), injury, noise exposure, and blockages in the ear canal. 8 Untreated infections, ototoxicity and ear blockages are the primary factors for hearing loss in L.M.I.C.s.
The number of people with disabling hearing loss is expected to double to 900 million people by 2050, 9 driven by:
A hearing aid is a rehabilitative device that amplifies sound frequencies for those with hearing impairment. Not all people with hearing loss will require or benefit from a hearing aid. Appropriateness of hearing aid use for an individual is dependent on the type (conductive or sensorineural; Table 1) 17 and severity 18 (mild to profound; Table 2) of hearing loss. 19 Hearing aids support improvement for varying degrees of hearing loss from mild to severe sensorineural hearing loss, which is caused by damage to the small sensory cells in the inner ear.
7TABLE 2: HEARING LOSS BY SEVERITY
W.H.O. estimates that more than 72 million people worldwide would benefit from the use of hearing aids, but only 10% of those that need it have it, with coverage at less than 3% in L.M.I.C.s. 20 This estimate is based on limited data and is considered by many experts to be an underestimate. The forthcoming World Hearing Report, which is expected to be published in 2020 by the W.H.O., will provide updated estimates of need.
For people with conductive hearing loss, for which hearing aids are not appropriate, medical treatments, such as antibiotic therapy or earwax removal performed by primary care healthcare workers or primary care physicians, or surgical treatments performed by Ear, Nose and Throat (E.N.T.) surgeons, may help resolve hearing issues. For example, W.H.O. estimates that 330 million of the 466 million people with disabling hearing loss suffer from chronic ear infections or chronic otitis media, 21 which can be resolved medically. Once the conductive hearing loss has been resolved, patients may require a hearing aid in case of sustained damage to the ear.
Studies show that quality of life is significantly lower among people with hearing loss, and people with hearing loss tend to secure lower rates of employment. Additionally, W.H.O. estimates that unaddressed hearing loss poses an annual global cost of U.S.$750 billion with a negative impact on education, social life and employability of those with hearing loss. 22 Negative outcomes associated with hearing loss can be attributed primarily to three factors: 23
Hearing aids can have a transformative impact on reducing the negative outcomes of hearing loss. A study conducted by World Wide Hearing (W.W.H.) and Sonrisas que Eschuchan Foundation in Guatemala in 2016 assessed the positive impact of hearing aids among 180 people with moderate to profound hearing loss. In less than a year of usage, the study found that 56% reported improved ability to communicate with family and friends and 88% reported that hearing aids had positively changed their enjoyment of life. 28
The continuum of care includes the following high-level steps:
Provision of hearing aids requires earmoulds and batteries over the life of the hearing aid:
EARDOMES.Many experts suggest the use of eardomes instead of earmoulds as a way to increase access, as they are factory made and do not require customisation (refer to Figure 3); however, they cannot be used for all users due to acoustic ventilation that can cause negative feedback loop or loss of amplification. Eardomes come in multiple sizes and the user can pick the one that is most comfortable. The cost of these eardomes is significantly lower than a custom earmould (< U.S.$0.10). 34
FIGURE 3: EARMOULDS AND EARDOMES
|
|
| Earmoulds | Eardomes |
W.H.O. developed the “Guidelines for Hearing Aids and Services for Developing Countries” 35 in 2004. Since hearing aid provision should happen in the context of E.H.C., W.H.O. supplemented these guidelines with the “Primary Ear and Hearing Care Training Resources” 36 in 2012 and with the “Preferred profile for hearing 12 aid technology suitable for L.M.I.C.s” in 2017 (henceforth referred to as the W.H.O. Preferred Product Profile or W.H.O. P.P.P.—refer to Appendix D.). 37
The 2004 Guidelines lack specificity on personnel, provision and product:
These also do not incorporate guidance on the latest advancements in technologies for screening and fitting earmoulds or hearing aids (discussed in section 4.12). Lastly, specific training resources for hearing aid provision in L.R.S. are limited. While audiologists and others in the sector may disagree on technical aspects of service delivery, there is a consensus that delivery must avail the use of audiometry, ensure appropriate fitting, and be provided in a context where long-term support is available. This consensus has been captured in the voluntary development of some guidelines and standards, such as the forthcoming “Suggested Guidelines for Humanitarian Hearing Care Outreach Programs” developed by the Coalition for Global Hearing Health. 38
Hearing aids are not one size fits all, and are differentiated by amplification power (the more severe the hearing loss, the higher the amplification power required), amplification technology (analogue vs. digital), sound processing capabilities, style (refer to Table 3 on hearing aid styles), battery types used, and special features (such as Bluetooth, Artificial Intelligence, etc.). Telecoil facility and compatibility 39 , direct audio input, directional microphones, etc. are also important functions of hearing aids that are necessary for long-term optimal use in various settings.
13TABLE 3: EXAMPLES OF HEARING AID STYLES 40
TABLE 4: ROUGH ESTIMATION OF THE PROPORTION OF DEVICES NEEDED IN L.M.I.C.S 41
| HEARING LOSS SEVERITY | MILD | MODERATE | SEVERE | PROFOUND |
| Recommended proportion | 10% | 45% | 35% | 10% |
Quality of hearing aids affects the user experience; poor sound quality, discomfort, or unreliability can lead to low usage rates or discontinuation. This limits the benefit that the user can derive from the hearing aids and makes it less likely that they will persevere until they find a quality product that works well. In addition, a poorer quality hearing aid can over-amplify some sounds, contributing to hearing damage. Lastly, while many products that are considered by experts as high quality meet moisture and dust resistant standards (such as I.P.67 42 , 43 ), they are still not well-suited for L.M.I.C. climates, which tend to be harsher than H.I.C. climates, and can often breakdown or get damaged quickly if not well protected.
The W.H.O. P.P.P. provides some guidance on aspects of quality but is not designed to be a rigorous quality standard. Many products match the W.H.O. P.P.P. on paper, but in practice have poor sound quality, are not durable, or are difficult to program by the provider. Unfortunately, there are no existing or planned standards for hearing aids that provide an objective measure of quality to inform procurement for low-resource settings. 44 According to experts, the U.S. F.D.A. and C.E. marks are not able to differentiate quality from non-quality products on the measure of hearing quality outlined above, and there is no globally recognised quality-testing programme. The F.D.A. requires certification of gains and output of hearing aids through a third party agency to ensure they match specifications but that is not a certification of quality. 45 While W.H.O.'s forthcoming Assistive Product Specifications (A.P.S.) will providing further clarity to procurers, they will not serve as an established quality standard.
In the absence of objective quality standards, private providers are loyal to certain manufacturers where they and their clients have had positive experiences with specific products, typically one of the leading global manufacturers. To maintain brand reputation, these manufacturers rigorously enforce internal quality standards. In seeking lower-cost alternatives, audiologists may conduct a “field test” of products, by having users try them for a certain period and then reporting their experiences with the products. The results of these tests are rarely published. 46 This leaves procurers without guidance on which hearing aids are of high quality and they often award contracts for hearing aids to the lowest bidder.
The global market for hearing aids is valued at U.S.$6 billion with more than 16 million hearing aids sold annually. 47 The market expects unit growth of 3% to 5% every year with 70% of units sold in Europe and North America. 48
TABLE 5: VALUE CHAIN IN THE PRIVATE SECTOR
The Big 5 have a limited presence in non-Western markets. For example, for William Demant, the Asia-Pacific accounts for 21% of unit sales, mostly from Japan and China. South America and Africa account for only 7% and 2% of unit sales, respectively. 49 The Big 5 see limited commercial interest in L.M.I.C.s due to the following factors:
WHITE LABEL BUNDLED PRODUCT AND SERVICE.Costco (U.S.) is the second-largest provider of hearing aids in the U.S. after the U.S. Veteran Affairs. The retailer's bundled price is U.S.$1,499 for a pair of hearing aids, 51 offering significant costs savings to users compared to traditional retail channels. It does so by:
By having a centralised payer or provider, public systems are able to conduct centralised procurement and leverage volumes to achieve reduced prices, thereby increasing adoption and accessibility of hearing aids. For example, while the penetration of hearing aids in many H.I.C. is on average only 20%, in countries such as Norway and the U.K., the strength of a publicly supported provision system has contributed to ~45% market coverage. 56 , 57 In these countries, governments play a critical role in providing the funding for products and provision, and negotiating terms with suppliers, while service provision may be delivered by either the public sector or contracted out to the private sector.
For example, N.H.S. England is a public procurer that conducts volume-based negotiation to drive down prices (refer to Case Study 4). U.K. tender information is made available on the E.U. website and is often consulted by E.U. countries that are procuring hearing aids. However, under U.K. regulations, other countries 19 are not able to procure from the procurement framework. 58 Over time, the prices have proved sustainable, and as volumes have increased, prices have further decreased. 59 The Clinical Commissioning Group for each local area within the N.H.S. sets the tariff for reimbursement of providers (both public and private) contracted to provide hearing services. The recommended tariff for 2016/2017 for hearing assessment, fitting of two hearing aids device, cost of two devices, and three years of follow up was around G.B.P.£370 but can vary based on a number of adjustment factors. 60
N.G.O.s have been able to access quality products at lower cost for humanitarian use (refer to Case Study 6). N.G.O.s, benefiting from these pricing agreements, believe that these humanitarian prices still incorporate a small profit margin for the manufacturer. Other models for procurement that N.G.O.s use, but that are less likely to be replicable at scale, include refurbishing donated product and accepting donated product from hearing aid companies through C.S.R.. 65
21These models also help overcome the need for the user to visit the audiology clinic multiple times before the hearing aids are working optimally and help reduce high drop-out or conversion rates. A study conducted in Malawi outlined that referral uptake for ear and hearing services was only 3% due to a variety of factors including location of the hospital, other indirect costs of seeking care, procedural problems within the outreach programme, awareness and understanding of hearing loss, and lack of visibility and availability of services. 67
Bulk manufacturing of hearing aids in centralised production factories is the standard manufacturing model employed by global suppliers. Production follows standard methods for small electronics manufacturing. Components such as microphones and transducers are sourced, while the hearing aid manufacturer is adding a plastic case and the proprietary software and assembles the final product. The production facilities, which are fairly automated, 69 are set up across the globe — most commonly in Asia — to optimise sourcing of components, assembly and distribution of hearing aids in L.M.I.C.s and H.I.C.s.
Local assembly of hearing aids has taken place in some countries such as Brazil, India, Botswana, Vietnam and the Philippines to attempt to reduce the burden of import duties on hearing aids. In such a model, manufacturers might be incentivised, if volumes are sufficient, to supply semi-knocked-down kits to local businesses that then assemble hearing aids. 70 Semi-knocked down kits usually require only soldering the transducer(s) onto the printed circuit board and closing the unit with small screws.
Traditional otoscopes are used for ear examinations and cost U.S.$100 to U.S.$4,000. Low cost otoscopes have been developed for use in L.M.I.C.s includig the Arclight costing around U.S.$10-15 and mobile-based otoscopes such as CellScope and Medtronic's Ear Screening Kit (see Case Study 8). While these otoscopes do not have the same levels of magnification, have some functional limitations, and have had limited clinical validation to date, 72 they are often preferred by N.G.O.s since they are lightweight, affordable and easy to use.
Product photos used with company permission.
Some of the advantages of these devices include:
The advent of new technology has also enabled the use of tele-audiology (refer to Case Study 9). This allows audiologists to diagnose, fit and provide rehabilitation services to people remotely, allowing for increased reach of services and stronger referral networks, as well as training and mentorship for hearing aid technicians. Recent reviews of tele-audiology have noted that there is an increasing role for tele-audiology and that it is feasible and likely effective, but may be limited by a lack of evidence protocols and models of service delivery, perceptions of tele-audiology by end users and clinicians, and resource constraints. 74
Discussions with experts 78 suggest that O.T.C. regulations could have a variety of benefits: 79
In 2018, the F.D.A. granted an application for the first Self-fitting Hearing Aid (S.F.H.A.) by Bose, which is yet to come to market. 80 According to the F.D.A., an S.F.H.A. is a wearable sound-amplifying device that is intended to compensate for impaired hearing and incorporates technology, including software that allows users to program their hearing aids through a smartphone. 81 Approval was granted because Bose submitted studies demonstrating that their S.F.H.A.s can provide similar sound amplification performance and experience to users as traditional hearing aids provided by a professional. 82 These devices are classified as a Class II medical device by F.D.A. and are targeted towards users over the age of 18 with mild to moderate hearing impairment. 83 These devices are currently considered to be separate from the O.T.C. hearing aid devices classified above as regulations on O.T.C. hearing aids are not yet established. Other S.F.H.A.s available in the market include devices that have been designated as hearing aids or personal sound amplification products dependent on country regulations, from Sound World Solutions and NuHeara. While S.F.H.A.s have not been extensively used in L.M.I.C.s, demonstration projects utilised Sound World Solutions' devices have shown that there is potential to use S.F.H.A.s to simplify provision. Low-skilled healthcare personnel can be more easily trained to fit self-fitting hearing aids as they allow for the automation of more complex tasks in the assessment and fitting process, reducing training requirements and expertise level.
| LEVEL (PERSONNEL) | PREVENTION / AWARENESS | SCREENING / DETECTION | TREATMENT / REHABILITATION |
SCREENING 86 involves identifying early signs of whether a person has hearing loss. In adults, it is usually through self-screening, as many are able to identify if there are suffering from hearing loss. This, however, is not always the case as a stigma associated with hearing loss prevents many people from acknowledging that they have hearing loss. For children under the age of five, there are objective tests such as: